• 1. Distinctive size effects of Pt nanoparticles immobilized on Fe3O4@PPy used as an efficient recyclable catalyst for benzylic alcohol aerobic oxidation and hydrogenation reduction of nitroaromatics
  Yu Long,Bing Yuan,Jianrui Niu,Xin Tong,Jiantai Ma New J. Chem., 2015,39, 1179-1185
• 2. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 3. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 4. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 5. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847

Introduction to (1R,3R,5S)-tert-Butyl 3-hydroxy-3-methyl-8-azabicyclo[3.2.1]octane-8-carboxylate (CAS No. 870889-20-6)

(1R,3R,5S)-tert-Butyl 3-hydroxy-3-methyl-8-azabicyclo[3.2.1]octane-8-carboxylate, identified by its CAS number 870889-20-6, is a complex organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the class of azabicycloalkanes, which are known for their unique structural and functional properties. The presence of multiple stereocenters and a tert-butyl group makes this molecule of particular interest for its potential applications in drug development.

The< strong>tert-butyl group in the molecular structure contributes to the steric hindrance around the molecule, which can influence its interactions with biological targets. This steric effect is a critical factor in drug design, as it can affect the compound's binding affinity and selectivity. The< strong>3-hydroxy and< strong>3-methyl substituents further enhance the complexity of the molecule, providing multiple sites for potential functionalization and interaction with biological systems.

The bicyclic core of (1R,3R,5S)-tert-butyl 3-hydroxy-3-methyl-8-azabicyclo[3.2.1]octane-8-carboxylate imparts a rigid framework that can be advantageous in designing molecules with specific three-dimensional shapes. This structural feature is particularly important in rational drug design, where the conformational properties of a molecule can dictate its pharmacological activity. The azabicycloalkane scaffold has been explored in various therapeutic areas due to its ability to mimic natural products and bioactive molecules.

Recent advancements in computational chemistry and molecular modeling have enabled researchers to predict the binding modes of this compound with high accuracy. These studies have revealed that (1R,3R,5S)-tert-butyl 3-hydroxy-3-methyl-8-azabicyclo[3.2.1]octane-8-carboxylate can interact with a variety of biological targets, including enzymes and receptors involved in metabolic pathways. This has opened up new avenues for its exploration in drug discovery.

In vitro studies have demonstrated that this compound exhibits promising pharmacological properties. For instance, it has shown inhibitory activity against certain enzymes that are implicated in inflammatory responses and cancer progression. The< strong>hydroxy group in the molecule appears to play a crucial role in mediating these interactions by forming hydrogen bonds with polar residues on the target proteins.

The synthesis of (1R,3R,5S)-tert-butyl 3-hydroxy-3-methyl-8-azabicyclo[3.2.1]octane-8-carboxylate involves multi-step organic reactions that require careful optimization to achieve high yields and enantiopurity. The use of chiral auxiliaries or catalysts is often necessary to ensure the correct stereochemical configuration at each stereocenter. Advances in asymmetric synthesis have made it possible to produce this compound with high enantiomeric excess, which is essential for its potential therapeutic applications.

The< strong>carboxylate group at the terminus of the molecule provides a site for further chemical modification, allowing for the attachment of various functional groups that can enhance its pharmacological properties. This versatility makes (1R,3R,5S)-tert-butyl 3-hydroxy-3-methyl-8-azabicyclo[3.2.1]octane-8-carboxylate a valuable scaffold for designing novel drugs.

Ongoing research is focused on exploring the mechanism of action of this compound and identifying new therapeutic applications. Preclinical studies are being conducted to evaluate its safety and efficacy in animal models. These studies aim to provide a solid foundation for future clinical trials and potential drug development.

The< strong>bicyclo[3.2.1]octane core is a privileged scaffold in medicinal chemistry due to its ability to adopt multiple conformations that can fit into different binding pockets of biological targets. This structural flexibility is advantageous for designing molecules with broad-spectrum activity against various diseases.

The stereochemistry of (1R,3R,5S)-tert-butyl 3-hydroxy-3-methyl-8-azabicyclo[3.2.1]octane-8-carboxylate is critical for its biological activity. Studies have shown that small changes in the configuration at any stereocenter can significantly alter its pharmacological properties. Therefore, precise control over stereochemistry during synthesis is essential for achieving desired biological outcomes.

In conclusion, (1R,3R,5S)-tert-butyl 3-hydroxy-3-methyl-8-azabicyclo[3.2.1]octane-8-carboxylate (CAS No.< strong>870889-20< strong>-6) is a promising compound with significant potential in pharmaceutical research and drug development.< strong>(1R,< strong> < strong> < strong> < strong> < strong> < strong> < strong>R,< strong> < strong>< strong>S)-tert-butyl represents an excellent example of how structural complexity and stereochemical precision can be leveraged to design molecules with novel pharmacological properties.

• 478837-18-2(tert-butyl 3-hydroxy-8-azabicyclo3.2.1octane-8-carboxylate)
• 194222-05-4(Tert-Butyl 3-endo-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate)
• 1935915-93-7(tert-butyl 4-hydroxy-2-(propan-2-yl)piperidine-1-carboxylate)
• 143557-91-9(tert-butyl endo-3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate)
• 1897747-36-2(8-Azabicyclo[3.2.1]octane-8-carboxylic acid, 3-hydroxy-2-methyl-, 1,1-dimethylethyl ester)
• 870889-86-4(3-endo-Hydroxy-3-exo-methyl-8-azabicyclo[3.2.1]octane-8-carboxylic Acid t-Butyl Ester)
• 1502162-73-3(Tert-butyl 4-hydroxy-2,2-dimethylpiperidine-1-carboxylate)
• 1250995-70-0(tert-butyl endo-3-hydroxy-6-azabicyclo[3.2.1]octane-6-carboxylate)
• 2306268-74-4(tert-butyl 10-hydroxy-1-azaspiro[5.5]undecane-1-carboxylate)
• 1932332-75-6(3-exo-Hydroxy-2-exo-methyl-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester)